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Abstract
Background: A change in a thyrometabolic state from severe hypothyroidism to thyrotoxicosis is very uncommon,
but possible in some circumstances.
Case presentation: A 27-year old female presented with clinical and biochemical thyrotoxicosis with a previous
history chemo- and radiotherapy (including the neck region) for a Hodgkin’s lymphoma (at the age of 18). At the
age of 20 this was followed by severe hypothyrodism [TSH > 100 μIU/mL (reference range: 0.27–4.2)]. She was
stated on L-thyroxine, but the dose was later reduced and subsequently discontinued. She had significantly
elevated titres of both
anti-thyroid peroxidase antibodies and anti-TSH-receptor antibodies throughout the course of disease. Thyroid
scintigraphy revealed a normal and homogenous iodine uptake.
Conclusions: We suspect that a gradual switch from
thyroid-blocking to thyroid-stimulating antibodies resulted in development of an overt thyrotoxicosis, possibly
with a contributory effect of neck irradiation on her autoimmune status.
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Background
Though severe hypothyroidism usually requires life-
long treatment with L-thyroxine, in rare circumstances
a remission of such state, or even a switch into thyro-
toxicosis could be observed. Below we present a case
of severe hypothyroidism followed by thyrotoxicosis in
a patient with a previous history of chemo- and radio-
therapy (including a neck irradiation) for a Hodgkin’s
lymphoma.
Case presentation
A 27-year old female presented with clinical and biochem-
ical thyrotoxicosis (TSH - 0.01 μIU/mL (ref. range: 0.27–
4.2 μIU/mL); free thyroxine (FT4) - 1.58 ng/dL (ref. range
0.98–1.63 ng/dL); free triiodothyronine (FT3) - 4.56 pg/
mL (ref. range 2.6–4.4 pg/mL). Clinical examination re-
vealed tachycardia about 100 beats/min and no obvious
goitre. Autoimmune profile was suggestive of Graves’ dis-
ease [anti-TSH-receptor antibodies (aTSHR) - 16.69 IU/L
(ref. 0–1.75), anti-thyroid peroxidase antibodies (aTPO) -
1780 IU/mL (ref.: 0–34 IU/mL)]. The patient had a history
of Hodgkin’s lymphoma, diagnosed and treated with
chemo- and radiotherapy (including the neck) at the
age of 18. At the age of 20 she developed severe
hypothyroidism (TSH > 100 μIU/ml), though with high ti-
tres of both aTPO (150 IU/mL) and aTSHR (37.56 IU/
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mL) antibodies. Thyroid function tests normalised after
treatment with L-thyroxine (100 μg o.d.). At the age of 26
she became “anxious” and experienced “heart palpita-
tions”. She was found to have suppressed TSH, that
remained suppressed even when the dose of L-thyroxine
was reduced and then discontinued. After further four
months she was found to have raised FT3 (see above).
Thyroid scintigraphy revealed a normal and homogenous
iodine uptake (41 %). The patient responded very well to
treatment with low dose thiamazole (10 mg od, later
5 mg o.d.) that was discontinued after about
12 months. About a year later (while 16-week preg-
nant) she was off medication and had mild subclinical
thyrotoxicosis (TSH - 0.035 μIU/mL, FT4 - 1.04 ng/
dL, FT3 - 3.09 pg/mL) and raised aTSHR antibodies,
albeit at lower titre than before (7.87 IU/L).
According to the literature data thyroid dysfunction is
one of the most common abnormalities seen after radio-
therapy for Hodgkin's disease that includes the neck [1].
Primary hypothyroidism, the most common radiation-
induced thyroid dysfunction, appears in 20–30 % pa-
tients who had therapeutic radiotherapy administered to
the neck region, and this usually occurs within the first
5 years after therapy (peak 2–3 years after treatment)
[1]. Irradiation of the thyroid may also increase the risk
of Graves' disease (relative risk 7.2–20.4), or Graves'
ophthalmopathy, thyroiditis, benign adenomas and thy-
roid cancer. The aetiology of radiation-induced thyroid
dysfunction includes vascular damage, parenchymal cell
damage and auto-immune reactions [1]. There are re-
ports, that after neck irradiation Graves’ disease may de-
velop in patients previously receiving thyroxine, and
indeed 33 % of the patients with Graves’ hyperthyroid-
ism had received thyroxine before its onset [2]. There-
fore thyroid hormone-replacement therapy in patients
with hypothyroidism after irradiation of the neck does
not eliminate risk of other thyroid abnormalities at a
later date. According to some authors, thyroiditis ob-
served in Hodgkin’s disease may be the result of immune
regulation disorders in Hodgkin’s disease [3]. Further-
more, a possibility of a change from hypo- to hyperthy-
roidism typical for Graves’ disease is has been known for
some time [4, 5], and was also confirmed in more recent
publications [6, 7].
Takeda et al. [8] demonstrated, by measuring changes in
cyclic AMP, that thyroid stimulating and thyroid blocking
antibodies may coexist within the same patient and their
relative activities may change over the course of the disease.
Our case illustrates that after neck irradiation, severe
hypothyroidism can be followed by thyrotoxicosis. It should
be noted that in our patient, both during hypo and hyper-
thyroidism, aTSHR were elevated. There are two types of
aTSHR: thyroid stimulating antibodies (TSAb) and TSH-
stimulation blocking antibodies (TBAb). TBAb block TSH-
stimulation of the thyroid and cause hypothyroidism. On
the other hand, TSAb stimulate the thyroid and result in
Graves’ hyperthyroidism. In our opinion, in this case there
was a gradual switch from TBAb into TSAb.
In some patients, TSAb and hyperthyroidism develop
unexpectedly after hypothyroidism that is caused by
TBAb [9]. Fan et al. [10] described a case with docu-
mented cycles of hypothyroidism alternating with hyper-
thyroidism. Also, as mentioned above, some hypothyroid
patients after irradiation of the neck, while treated for
the Hodgkin's disease, developed hyperthyroidism [2]. A
number of mechanisms may be involved in switching
from TBAb to TSAb. Significantly, thyroxine treatment
in some patients is associated with increase TSAb that -
in extreme cases - might lead to development of hyper-
thyroidism in hypothyroid patients [9], though whether
this was a case in our patient is speculative as neck ir-
radiation per se is considered to be capable of influen-
cing changes in patients’ immune status.
Conclusions
Our case demonstrates a possibility of a switch from se-
vere hypothyroidism to thyrotoxicosis, possibly due to a
gradual change from TBAb to TSAb in a patient with a
previous history of neck irradiation for Hodgkin’s
lymphoma. Therefore, thyroid hormone-replacement
therapy in patients with hypothyroidism after irradiation
of the neck does not eliminate a risk of later thyroid
abnormalities.
The case reported above has been preliminarily pre-
sented for educational purposes during the conference
“Spring School of Thyroidology” organized by the Polish
Thyroid Association, 2014 [11].
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KCL, KD, JM and AL - clinical management, acquisition of data and
preparation of the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
This study was supported by statutory funds from the Department of
Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital -
Research Institute, Lodz, Poland.
Author details
1Department of Endocrinology and Metabolic Diseases, Polish Mother’s
Memorial Hospital - Research Institute, Lodz, Poland. 2Department of
Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz,
Poland. 3Department of Nuclear Medicine and Oncological Endocrinology,
Zgierz District Hospital, Zgierz, Poland.
Lewandowski et al. Thyroid Research  (2016) 9:1 Page 2 of 3
Received: 10 November 2015 Accepted: 6 January 2016
References
1. Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R.
Radiotherapy-induced thyroid disorders. Cancer Treat Rev. 2004;30:369–84.
2. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of
Hodgkin's disease. N Engl J Med. 1991;325:599–605.
3. Illés A, Bíró E, Miltényi Z, Keresztes K, Váróczy L, András C, et al.
Hypothyroidism and thyroiditis after therapy for Hodgkin's disease. Acta
Haematol. 2003;109:11–7.
4. Rivera JV, Reyes FM. Myxedema preceding thyrotoxicosis in Graves’ disease.
Bol Asoc Med PR. 1968;60:438–42.
5. Olczak S, McCulloch AJ, Clark F. Thyrotoxic Graves's disease after primary
hypothyroidism. Br Med J. 1978;2(6138):666.
6. Szczepanek-Parulska E, Ruchala M, Hernik A. Unexpected conversion from
hypothyroidism to an euthyroid state due to Graves' disease in a patient
with an ectopic thyroid. Endocrine. 2014;46:684–5.
7. Furgan S, Haque NU, Islam N. Conversion of autoimmune hypothyroidism
to hyperthyroidism. BMC Res Notes. 2014;7:489.
8. Takeda K, Tamatsu J, Kasagi K, Sakane S, Ikegami Y, Isotani H, et al.
Development of hyperthyroidism following primary hypothyroidism: a case
report with changes in thyroid-related antibodies. Clin Endocrinol (Oxf).
1988;28:341–4.
9. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and
thyroid-stimulating autoantibodies: potential mechanisms involved in the
pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
Thyroid. 2013;23:14–24.
10. Fan W, Tandon P, Krishnamurthy M. Oscillating hypothyroidism and
hyperthyroidism - a case-based review. J Community Hosp Int Med
Perspect. 2014;4:25734.
11. Lewandowski K, Dabrowska K, Makarewicz J, Lewinski A. Pendulum swings
from hypo- to hyperthyroidism: thyrotoxicosis after severe hypothyroidism
after neck irradiation in a patient with a history of Hodgkin's lymphoma.
Thyroid Res. 2015;8(Suppl 1 - Abstracts of invited lectures):A18.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lewandowski et al. Thyroid Research  (2016) 9:1 Page 3 of 3
